Evaluating the Feasibility and Acceptability of Inhalation Aromatherapy for Patients Undergoing Autologous Haematopoietic Stem Cell Transplant (HSCT)
NCT07209501 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-12-22
Summary
The goal of this clinical trial is to evaluate whether aromatherapy inhaler sticks can reduce nausea and vomiting in patients receiving chemotherapy as part of their stem cell transplant treatment. The main questions it aims to answer are:
* Can aromatherapy inhaler sticks be practically used by patients undergoing stem cell transplant (feasibility)?
* Do patients find aromatherapy inhaler sticks acceptable to use during their treatment?
* How effective are aromatherapy inhaler sticks at reducing chemotherapy-induced nausea and vomiting?
* What are patients' experiences when using aromatherapy during stem cell transplant?
Researchers will compare patients using aromatherapy inhaler sticks with essential oils to patients using inhaler sticks with only jojoba oil (placebo) to see if the essential oils provide additional benefits for reducing nausea and vomiting.
Participants will:
* Use their assigned inhaler stick every four hours when awake and whenever they feel nauseous
* Hold the inhaler stick a finger's length from their nostrils and inhale through one nostril at a time
* Use the inhaler stick for no more than 5 minutes per session
* Begin using the inhaler on the day of chemotherapy and continue until five days after chemotherapy completion (total of six days)
* Receive standard care for nausea and vomiting alongside the inhaler stick
* Complete study journals to record their experiences This is a single-blinded study, meaning participants will not know whether they received the aromatherapy or placebo inhaler stick.
Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
- OTHER
-
Aromatherapy inhaler
Participants in the intervention group will receive inhalation therapy via an aromatherapy inhaler stick\*, on top of standard care. Participants will be instructed to use the inhaler stick every four hours when they are awake, and whenever they feel nauseous, by holding the inhaler stick a finger's length away from their nostrils and inhaling through one nostril at a time. Each inhaler administration should not last more than 5 minutes. Participants will commence using the inhaler stick on the day of chemotherapy, until five days after the completion of chemotherapy (total of six days). Given the subjective nature of scents, participants in the intervention group will be given a choice between two therapeutic aroma blends - N1 and N2 - before commencing the study. This approach aims to minimize the risk of negative associations with a particular scent and enhance participant adherence to the intervention.
- OTHER
-
Aromatherapy inhaler (placebo)
Participants in the control group will receive the placebo intervention in addition to standard care. They will be provided with an identical aromatherapy inhaler stick infused solely with jojoba oil. Jojoba oil, primarily used as a carrier oil for dilution, has littleto- no scent and no known therapeutic or anxiolytic effects when inhaled.
Sponsors & Collaborators
-
Singapore General Hospital
lead OTHER -
National Cancer Centre, Singapore
collaborator OTHER
Principal Investigators
-
Cheryl Tay, Bachelor of Nursing · Singapore General Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-05-15
- Primary Completion
- 2026-06-23
- Completion
- 2026-06-24
Countries
- Singapore
Study Locations
More Related Trials
-
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
NCT05841849 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea
NCT04937309 ·Status: UNKNOWN ·Phase: NA
-
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
NCT02400866 ·Status: UNKNOWN ·Phase: PHASE2
-
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
NCT00553059 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
NCT00211601 ·Status: COMPLETED ·Phase: NA
-
Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting
NCT05143554 ·Status: TERMINATED ·Phase: NA
-
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
NCT00900068 ·Status: TERMINATED
-
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
NCT00273468 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting
NCT01937156 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
NCT03079219 ·Status: COMPLETED ·Phase: PHASE3
-
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
NCT02116530 ·Status: COMPLETED ·Phase: PHASE3
-
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
NCT00248547 ·Status: COMPLETED ·Phase: NA
-
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
NCT03571126 ·Status: UNKNOWN ·Phase: PHASE4
-
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
NCT04592198 ·Status: COMPLETED ·Phase: PHASE2
-
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
NCT04150614 ·Status: RECRUITING ·Phase: PHASE4
-
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
NCT00795769 ·Status: COMPLETED ·Phase: PHASE2
-
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
NCT01649258 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
NCT02576327 ·Status: UNKNOWN ·Phase: PHASE4
-
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
NCT05872893 ·Status: UNKNOWN ·Phase: PHASE3
-
Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV
NCT05805800 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study
NCT04536558 ·Status: UNKNOWN ·Phase: PHASE3
-
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
NCT04472143 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
NCT00719173 ·Status: COMPLETED ·Phase: PHASE1
-
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
NCT01736917 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851 ·Status: RECRUITING ·Phase: PHASE2